Company intelligence / Profile preview

Pharma Two B

Kiryat Ono, Israel

Ownership: Private
Development stage: Phase 3

Overview

P2B001 demonstrated benefits comparable to marketed pramipexole ER in Phase 3 trials but with fewer daytime sleep-related and dopaminergic side effects. The company owns worldwide patents covering both composition and method of treatment with P2B001. NDA submission planned for H1/2026.

Therapeutic areas: OncologyNeurology
Modalities: Small moleculesCombination products based on previously approved drugs
Industry: Biotech

Drug pipeline

1 asset

pramipexole + rasagiline

Phase 3

Indications: Parkinson's disease

Partnerships

No major pharma partnerships disclosed publicly.

Beyond the preview

Go deeper on Pharma Two B.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pharma Two B.

Explore the full profile